Metoprolol in Critically Ill Patients With COVID-19

[1]  J. Haynes,et al.  COVID-19: a simple statistical model for predicting intensive care unit load in exponential phases of the disease , 2021, Scientific Reports.

[2]  R. Curi,et al.  COVID-19 and Neutrophils: The Relationship between Hyperinflammation and Neutrophil Extracellular Traps , 2020, Mediators of inflammation.

[3]  L. Cavalcante-Silva,et al.  Neutrophils and COVID-19: The road so far , 2020, International Immunopharmacology.

[4]  T. Hwang,et al.  Targeting Neutrophils to Treat Acute Respiratory Distress Syndrome in Coronavirus Disease , 2020, Frontiers in Pharmacology.

[5]  V. Fuster,et al.  Metoprolol exerts a non-class effect against ischaemia–reperfusion injury by abrogating exacerbated inflammation , 2020, European heart journal.

[6]  Alexander Sczyrba,et al.  Severe COVID-19 Is Marked by a Dysregulated Myeloid Cell Compartment , 2020, Cell.

[7]  B. Ibáñez.  Intravenous β-blockers in STEMI: what you are about to do, do it quickly , 2020, European heart journal. Acute cardiovascular care.

[8]  E. Arbustini,et al.  Broncho-alveolar inflammation in COVID-19 patients: a correlation with clinical outcome , 2020, BMC Pulmonary Medicine.

[9]  Robert A. Campbell,et al.  Neutrophil extracellular traps contribute to immunothrombosis in COVID-19 acute respiratory distress syndrome , 2020, Blood.

[10]  H. Anders,et al.  Neutrophils and Neutrophil Extracellular Traps Drive Necroinflammation in COVID-19 , 2020, Cells.

[11]  J. Knight,et al.  Neutrophil extracellular traps and thrombosis in COVID-19 , 2020, medRxiv.

[12]  R. Woods,et al.  Neutrophil extracellular traps in COVID-19. , 2020, JCI insight.

[13]  J. González-Martín,et al.  Dexamethasone treatment for the acute respiratory distress syndrome: a multicentre, randomised controlled trial. , 2020, The Lancet. Respiratory medicine.

[14]  Chao He,et al.  C(C)Learing the Role of Chemokines in Pulmonary Fibrosis , 2020, American journal of respiratory cell and molecular biology.

[15]  E. Oliver,et al.  Beta-blockers: Historical perspective and mechanisms of action. , 2019, Revista espanola de cardiologia.

[16]  M. Nalos,et al.  The association between premorbid beta blocker exposure and mortality in sepsis—a systematic review , 2019, Critical Care.

[17]  A. Vargas,et al.  Neutrophil extracellular traps are downregulated by glucocorticosteroids in lungs in an equine model of asthma , 2017, Respiratory Research.

[18]  V. Fuster,et al.  Neutrophil stunning by metoprolol reduces infarct size , 2017, Nature Communications.

[19]  V. Fuster,et al.  Impact of the Timing of Metoprolol Administration During STEMI on Infarct Size and Ventricular Function. , 2016, Journal of the American College of Cardiology.

[20]  M. Balaan,et al.  Acute Respiratory Distress Syndrome , 2016, Critical care nursing quarterly.

[21]  T. Standiford,et al.  Therapeutic targeting of acute lung injury and acute respiratory distress syndrome. , 2016, Translational research : the journal of laboratory and clinical medicine.

[22]  M. Gong,et al.  Lung-protective ventilation in acute respiratory distress syndrome. How soon is now? , 2015, American journal of respiratory and critical care medicine.

[23]  V. Fuster,et al.  Long-term benefit of early pre-reperfusion metoprolol administration in patients with acute myocardial infarction: results from the METOCARD-CNIC trial (Effect of Metoprolol in Cardioprotection During an Acute Myocardial Infarction). , 2014, Journal of the American College of Cardiology.

[24]  B. Freedman,et al.  Staphylococcus aureus Leukotoxin GH Promotes Formation of Neutrophil Extracellular Traps , 2013, The Journal of Immunology.

[25]  M. Singer,et al.  Effect of heart rate control with esmolol on hemodynamic and clinical outcomes in patients with septic shock: a randomized clinical trial. , 2013, JAMA.

[26]  A. Mebazaa,et al.  Microvascular Effects of Heart Rate Control With Esmolol in Patients With Septic Shock: A Pilot Study* , 2013, Critical care medicine.

[27]  M. van der Jagt,et al.  Beta-blockers in intensive care medicine: potential benefit in acute brain injury and acute respiratory distress syndrome. , 2012, Recent patents on cardiovascular drug discovery.

[28]  S. Lemeshow,et al.  Preadmission beta-blocker use and 30-day mortality among patients in intensive care: a cohort study , 2011, Critical care.

[29]  A. Mebazaa,et al.  Effect of oral beta-blocker on short and long-term mortality in patients with acute respiratory failure: results from the BASEL-II-ICU study , 2010, Critical care.

[30]  Z. Werb,et al.  Netting neutrophils in autoimmune small-vessel vasculitis , 2009, Nature Medicine.

[31]  D. Dries.  Beta-Blockers in Isolated Blunt Head Injury , 2009 .

[32]  H. Ulmer,et al.  Combined milrinone and enteral metoprolol therapy in patients with septic myocardial depression , 2008, Critical care.

[33]  P. Arbogast,et al.  Beta-blocker exposure is associated with improved survival after severe traumatic brain injury. , 2007, The Journal of trauma.

[34]  S. Baudouin.  Manipulation of inflammation in ARDS: achievable goal or distant target? , 2006, Thorax.

[35]  Heinrich Leonhardt,et al.  DNA labeling in living cells , 2005, Cytometry. Part A : the journal of the International Society for Analytical Cytology.

[36]  T. Nicolai,et al.  A role for MCP-1/CCR2 in interstitial lung disease in children , 2005, Respiratory research.

[37]  R. Errington,et al.  DRAQ5 Labeling of Nuclear DNA in Live and Fixed Cells , 2004, Current protocols in cytometry.

[38]  C. Haas.  Lung protective mechanical ventilation in acute respiratory distress syndrome. , 2003, Respiratory care clinics of North America.

[39]  B. Brando,et al.  Enumeration of Absolute Cell Counts Using Immunophenotypic Techniques , 2000, Current protocols in cytometry.